| Symbol | EWTX |
|---|---|
| Name | EDGEWISE THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 1715 38TH ST, BOULDER, Colorado, 80301, United States |
| Telephone | +1 720 262-7002 |
| Fax | — |
| — | |
| Website | https://www.edgewisetx.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001710072 |
| Description | Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. Additional info from NASDAQ: |
2026-05-07 18:18
New Form S-8 - Edgewise Therapeutics, Inc. <b>Filed:</b> 2026-05-07 <b>AccNo:</b> 0001104659-26-057287 <b>Size:</b> 253 KB
Read more
2026-05-07 13:20
(30% Negative) EDGEWISE THERAPEUTICS, INC. (EWTX) Reports Q2 2026 Financial Results
Read more
2026-05-07 12:01
Edgewise Therapeutics - Edgewise Therapeutics Reports First Quarter 2026 Financial Results and Advances Clinical Programs in Muscular Dystrophy and Cardiovascular Indications
Read more
2026-05-05 17:15
Donovan Joanne M. 🟡 adjusted position in 55.2K shares (1 derivative) of Edgewise Therapeutics, Inc. (EWTX) at $38.57 ($2.8M) Transaction Date: May 04, 2026 | Filing ID: 000004
Read more
2026-05-04 12:01
Edgewise Therapeutics - Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
Read more
2026-05-04 12:00
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
Read more
2026-04-27 17:50
New Form SCHEDULE 13D/A - Edgewise Therapeutics, Inc. <b>Filed:</b> 2026-04-27 <b>AccNo:</b> 0001388325-26-000014 <b>Size:</b> 31 KB
Read more
2026-04-23 17:10
New Form ARS - Edgewise Therapeutics, Inc. <b>Filed:</b> 2026-04-23 <b>AccNo:</b> 0001104659-26-047696 <b>Size:</b> 3 MB
Read more
2026-04-23 17:07
New Form DEFA14A - Edgewise Therapeutics, Inc. <b>Filed:</b> 2026-04-23 <b>AccNo:</b> 0001104659-26-047691 <b>Size:</b> 369 KB
Read more
2026-04-23 17:07
New Form DEF 14A - Edgewise Therapeutics, Inc. <b>Filed:</b> 2026-04-23 <b>AccNo:</b> 0001104659-26-047688 <b>Size:</b> 3 MB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07456059 | A Study to Evaluate EDG-7500 in Caucasian and Japanese Adults | Phase1 | Healthy Adult Participants | Not_Yet_Recruiting | 2026-03-01 | 2026-06-01 | ClinicalTrials.gov |
| NCT07324616 | A Study to Evaluate EDG-7500 in Adults With Hepatic Impairment | Phase1 | Hepatic Impairment (HI) | Recruiting | 2026-01-26 | 2026-05-01 | ClinicalTrials.gov |
| NCT07177066 | A Study of EDG-15400 in Healthy Adults | Phase1 | Healthy Adults | Recruiting | 2025-08-20 | 2026-05-01 | ClinicalTrials.gov |
| NCT07034768 | A Study to Evaluate EDG-7500 in People With Renal Impairment | Phase1 | Renal Impairments | Completed | 2025-07-22 | 2025-12-26 | ClinicalTrials.gov |
| NCT06916897 | A Study to Evaluate Effect of Verapamil and Food of Sevasemten in Healthy Volun… | Phase1 | Healthy Subjects | Completed | 2025-01-08 | 2025-02-22 | ClinicalTrials.gov |
| NCT06738836 | A Study to Evaluate the Absorption, Metabolism, And Excretion Of Orally Adminis… | Phase1 | Healthy Volunteer | Completed | 2024-12-03 | 2025-01-17 | ClinicalTrials.gov |
| NCT06347159 | A Study of EDG-7500 in Adults With Hypertrophic Cardiomyopathy (CIRRUS-HCM) | Phase2 | Hypertrophic Cardiomyopathy | Active_Not_Recruiting | 2024-04-11 | 2026-12-01 | ClinicalTrials.gov |
| NCT06100887 | Phase 2 Study of EDG-5506 in Children and Adolescents With Duchenne Muscular Dy… | Phase2 | Duchenne Muscular Dystrophy | Active_Not_Recruiting | 2024-03-22 | 2027-03-01 | ClinicalTrials.gov |
| NCT06066580 | Open-Label Extension of EDG-5506 in Participants With Becker Muscular Dystrophy | Phase2 | Becker Muscular Dystrophy | Enrolling_By_Invitation | 2023-11-02 | 2031-02-01 | ClinicalTrials.gov |
| NCT06011317 | A Study of EDG-7500 in Healthy Adults | Phase1 | Healthy Subjects | Completed | 2023-08-14 | 2024-06-20 | ClinicalTrials.gov |
| NCT05730842 | Absorption, Metabolism, Excretion and Absolute Bioavailability of EDG-5506 in H… | Phase1 | Healthy Volunteer | Completed | 2023-01-12 | 2023-04-06 | ClinicalTrials.gov |
| NCT05291091 | Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON) | Phase2 | Becker Muscular Dystrophy | Active_Not_Recruiting | 2022-11-10 | 2026-09-01 | ClinicalTrials.gov |
| NCT05540860 | A Study of EDG-5506 in Children With Duchenne Muscular Dystrophy (LYNX) | Phase2 | Duchenne Muscular Dystrophy | Active_Not_Recruiting | 2022-10-24 | 2027-01-01 | ClinicalTrials.gov |
| NCT05492734 | A Study to Assess the Feasibility of Non-invasive Dried Blood Sampling | Phase1 | Muscular Dystrophies | Completed | 2022-08-12 | 2022-08-19 | ClinicalTrials.gov |
| NCT05257473 | Defining Endpoints in Becker Muscular Dystrophy | — | Becker Muscular Dystrophy | Active_Not_Recruiting | 2022-04-13 | 2026-05-01 | ClinicalTrials.gov |
| NCT05160415 | A Study of EDG-5506 in Adult Males With Becker Muscular Dystrophy | Phase1 | Becker Muscular Dystrophy | Completed | 2021-12-28 | 2024-03-01 | ClinicalTrials.gov |
| NCT04585464 | A Study to Assess Safety, Tolerability, and PK of EDG-5506 in Healthy Volunteer… | Phase1 | Healthy Volunteer | Completed | 2020-10-12 | 2021-12-27 | ClinicalTrials.gov |
| NCT04349566 | Fast Troponin as a Biomarker to Assess Exercise-induced Muscle Damage in Muscle… | — | Becker Muscular Dystrophy | Completed | 2020-06-01 | 2021-12-20 | ClinicalTrials.gov |
Total clinical trials: 18
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Sevasemten | Other | Phase PHASE2 | Becker Muscular Dystrophy | ENROLLING_BY_INVITATION | NCT06066580 |
| Sevasemten | Other | Phase PHASE2 | Becker Muscular Dystrophy | ENROLLING_BY_INVITATION | NCT06066580 |
| Sevasemten | Other | Phase PHASE2 | Becker Muscular Dystrophy | ENROLLING_BY_INVITATION | NCT06066580 |
| Sevasemten | Other | Phase PHASE2 | Becker Muscular Dystrophy | ENROLLING_BY_INVITATION | NCT06066580 |
| Sevasemten | Other | Phase PHASE2 | Becker Muscular Dystrophy | ENROLLING_BY_INVITATION | NCT06066580 |
| Sevasemten | Other | Phase PHASE2 | Becker Muscular Dystrophy | ENROLLING_BY_INVITATION | NCT06066580 |
| Sevasemten | Other | Phase PHASE2 | Becker Muscular Dystrophy | ENROLLING_BY_INVITATION | NCT06066580 |
| Sevasemten | Other | Phase PHASE2 | Becker Muscular Dystrophy | ENROLLING_BY_INVITATION | NCT06066580 |
| Placebo | Other | Phase PHASE2 | Becker Muscular Dystrophy | ACTIVE_NOT_RECRUITING | NCT05291091 |
| Sevasemten 12.5 mg | Other | Phase PHASE2 | Becker Muscular Dystrophy | ACTIVE_NOT_RECRUITING | NCT05291091 |
| Sevasemten 5 mg | Other | Phase PHASE2 | Becker Muscular Dystrophy | ACTIVE_NOT_RECRUITING | NCT05291091 |
| Sevasemten 10 mg | Other | Phase PHASE2 | Becker Muscular Dystrophy | ACTIVE_NOT_RECRUITING | NCT05291091 |
| Placebo | Other | Phase PHASE2 | Becker Muscular Dystrophy | ACTIVE_NOT_RECRUITING | NCT05291091 |
| Sevasemten 12.5 mg | Other | Phase PHASE2 | Becker Muscular Dystrophy | ACTIVE_NOT_RECRUITING | NCT05291091 |
| Sevasemten 5 mg | Other | Phase PHASE2 | Becker Muscular Dystrophy | ACTIVE_NOT_RECRUITING | NCT05291091 |
| Sevasemten 10 mg | Other | Phase PHASE2 | Becker Muscular Dystrophy | ACTIVE_NOT_RECRUITING | NCT05291091 |
| Placebo | Other | Phase PHASE2 | Becker Muscular Dystrophy | ACTIVE_NOT_RECRUITING | NCT05291091 |
| Sevasemten 12.5 mg | Other | Phase PHASE2 | Becker Muscular Dystrophy | ACTIVE_NOT_RECRUITING | NCT05291091 |
| Sevasemten 5 mg | Other | Phase PHASE2 | Becker Muscular Dystrophy | ACTIVE_NOT_RECRUITING | NCT05291091 |
| Sevasemten 10 mg | Other | Phase PHASE2 | Becker Muscular Dystrophy | ACTIVE_NOT_RECRUITING | NCT05291091 |
| Placebo | Other | Phase PHASE2 | Becker Muscular Dystrophy | ACTIVE_NOT_RECRUITING | NCT05291091 |
| Sevasemten 12.5 mg | Other | Phase PHASE2 | Becker Muscular Dystrophy | ACTIVE_NOT_RECRUITING | NCT05291091 |
| Sevasemten 5 mg | Other | Phase PHASE2 | Becker Muscular Dystrophy | ACTIVE_NOT_RECRUITING | NCT05291091 |
| Sevasemten 10 mg | Other | Phase PHASE2 | Becker Muscular Dystrophy | ACTIVE_NOT_RECRUITING | NCT05291091 |
| Placebo | Other | Phase PHASE2 | Becker Muscular Dystrophy | ACTIVE_NOT_RECRUITING | NCT05291091 |
| Sevasemten 12.5 mg | Other | Phase PHASE2 | Becker Muscular Dystrophy | ACTIVE_NOT_RECRUITING | NCT05291091 |
| Sevasemten 5 mg | Other | Phase PHASE2 | Becker Muscular Dystrophy | ACTIVE_NOT_RECRUITING | NCT05291091 |
| Sevasemten 10 mg | Other | Phase PHASE2 | Becker Muscular Dystrophy | ACTIVE_NOT_RECRUITING | NCT05291091 |
| Placebo | Other | Phase PHASE2 | Becker Muscular Dystrophy | ACTIVE_NOT_RECRUITING | NCT05291091 |
| Sevasemten 12.5 mg | Other | Phase PHASE2 | Becker Muscular Dystrophy | ACTIVE_NOT_RECRUITING | NCT05291091 |
| Sevasemten 5 mg | Other | Phase PHASE2 | Becker Muscular Dystrophy | ACTIVE_NOT_RECRUITING | NCT05291091 |
| Sevasemten 10 mg | Other | Phase PHASE2 | Becker Muscular Dystrophy | ACTIVE_NOT_RECRUITING | NCT05291091 |
| Placebo | Other | Phase PHASE2 | Becker Muscular Dystrophy | ACTIVE_NOT_RECRUITING | NCT05291091 |
| Sevasemten 12.5 mg | Other | Phase PHASE2 | Becker Muscular Dystrophy | ACTIVE_NOT_RECRUITING | NCT05291091 |
| Sevasemten 5 mg | Other | Phase PHASE2 | Becker Muscular Dystrophy | ACTIVE_NOT_RECRUITING | NCT05291091 |
| Sevasemten 10 mg | Other | Phase PHASE2 | Becker Muscular Dystrophy | ACTIVE_NOT_RECRUITING | NCT05291091 |
| Placebo | Other | Phase PHASE2 | Becker Muscular Dystrophy | ACTIVE_NOT_RECRUITING | NCT05291091 |
| Sevasemten 12.5 mg | Other | Phase PHASE2 | Becker Muscular Dystrophy | ACTIVE_NOT_RECRUITING | NCT05291091 |
| Sevasemten 5 mg | Other | Phase PHASE2 | Becker Muscular Dystrophy | ACTIVE_NOT_RECRUITING | NCT05291091 |
| Sevasemten 10 mg | Other | Phase PHASE2 | Becker Muscular Dystrophy | ACTIVE_NOT_RECRUITING | NCT05291091 |
| Placebo | Other | Phase PHASE2 | Becker Muscular Dystrophy | ACTIVE_NOT_RECRUITING | NCT05291091 |
| Sevasemten 12.5 mg | Other | Phase PHASE2 | Becker Muscular Dystrophy | ACTIVE_NOT_RECRUITING | NCT05291091 |
| Sevasemten 5 mg | Other | Phase PHASE2 | Becker Muscular Dystrophy | ACTIVE_NOT_RECRUITING | NCT05291091 |
| Sevasemten 10 mg | Other | Phase PHASE2 | Becker Muscular Dystrophy | ACTIVE_NOT_RECRUITING | NCT05291091 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT04585464 |
| EDG-5506 | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT04585464 |
| EDG-5506 | Other | Phase PHASE1 | Muscular Dystrophies | COMPLETED | NCT05492734 |
| Radiolabeled EDG-5506 Intravenous | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT05730842 |
| Radiolabeled EDG-5506 Suspension | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT05730842 |
| EDG-5506 Tablet | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT05730842 |
| Placebo | Other | Phase PHASE1 | Healthy Subjects | COMPLETED | NCT06011317 |
| EDG-7500 | Other | Phase PHASE1 | Healthy Subjects | COMPLETED | NCT06011317 |
| Verapamil | Other | Phase PHASE1 | Healthy Subjects | COMPLETED | NCT06916897 |
| sevasemten | Other | Phase PHASE1 | Healthy Subjects | COMPLETED | NCT06916897 |
| [14C]-EDG-7500 | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06738836 |
| Sevasemten | Other | Phase PHASE1 | Becker Muscular Dystrophy | COMPLETED | NCT05160415 |
| Placebo | Other | Phase PHASE1 | Healthy Adults | RECRUITING | NCT07177066 |
| EDG-15400 | Other | Phase PHASE1 | Healthy Adults | RECRUITING | NCT07177066 |
| Placebo | Other | Phase PHASE2 | Duchenne Muscular Dystrophy | ACTIVE_NOT_RECRUITING | NCT06100887 |
| Sevasemten Dose 3 | Other | Phase PHASE2 | Duchenne Muscular Dystrophy | ACTIVE_NOT_RECRUITING | NCT06100887 |
| Sevasemten Dose 2 | Other | Phase PHASE2 | Duchenne Muscular Dystrophy | ACTIVE_NOT_RECRUITING | NCT06100887 |
| Sevasemten Dose 1 | Other | Phase PHASE2 | Duchenne Muscular Dystrophy | ACTIVE_NOT_RECRUITING | NCT06100887 |
| Placebo | Other | Phase PHASE2 | Duchenne Muscular Dystrophy | ACTIVE_NOT_RECRUITING | NCT05540860 |
| Sevasemten Dose 5 | Other | Phase PHASE2 | Duchenne Muscular Dystrophy | ACTIVE_NOT_RECRUITING | NCT05540860 |
| Sevasemten Dose 4 | Other | Phase PHASE2 | Duchenne Muscular Dystrophy | ACTIVE_NOT_RECRUITING | NCT05540860 |
| Sevasemten Dose 3 | Other | Phase PHASE2 | Duchenne Muscular Dystrophy | ACTIVE_NOT_RECRUITING | NCT05540860 |
| Sevasemten Dose 2 | Other | Phase PHASE2 | Duchenne Muscular Dystrophy | ACTIVE_NOT_RECRUITING | NCT05540860 |
| Sevasemten Dose 1 | Other | Phase PHASE2 | Duchenne Muscular Dystrophy | ACTIVE_NOT_RECRUITING | NCT05540860 |
| EDG-7500 | Other | Phase PHASE2 | Hypertrophic Cardiomyopathy | ACTIVE_NOT_RECRUITING | NCT06347159 |
| EDG-7500 | Other | Phase PHASE1 | Healthy Adult Participants | NOT_YET_RECRUITING | NCT07456059 |
| EDG-7500 | Other | Phase PHASE1 | Hepatic Impairment (HI) | RECRUITING | NCT07324616 |
| EDG-7500 | Other | Phase PHASE1 | Renal Impairments | COMPLETED | NCT07034768 |
| Sevasemten | Other | Phase PHASE2 | Becker Muscular Dystrophy | ENROLLING_BY_INVITATION | NCT06066580 |
| Placebo | Other | Phase PHASE2 | Becker Muscular Dystrophy | ACTIVE_NOT_RECRUITING | NCT05291091 |
| Sevasemten 12.5 mg | Other | Phase PHASE2 | Becker Muscular Dystrophy | ACTIVE_NOT_RECRUITING | NCT05291091 |
| Sevasemten 5 mg | Other | Phase PHASE2 | Becker Muscular Dystrophy | ACTIVE_NOT_RECRUITING | NCT05291091 |
| Sevasemten 10 mg | Other | Phase PHASE2 | Becker Muscular Dystrophy | ACTIVE_NOT_RECRUITING | NCT05291091 |
| EDG-15400 | DRUG | Phase PHASE1 | Healthy Adults | RECRUITING | NCT07177066 |
| Verapamil | DRUG | Phase PHASE1 | Healthy Subjects | COMPLETED | NCT06916897 |
| sevasemten | DRUG | Phase PHASE1 | Healthy Subjects | COMPLETED | NCT06916897 |
| [14C]-EDG-7500 | DRUG | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06738836 |
| EDG-7500 | DRUG | Phase PHASE1 | Healthy Adult Participants | NOT_YET_RECRUITING | NCT07456059 |
| Radiolabeled EDG-5506 Intravenous | DRUG | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT05730842 |
| Radiolabeled EDG-5506 Suspension | DRUG | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT05730842 |
| EDG-5506 Tablet | DRUG | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT05730842 |
| Sevasemten Dose 5 | DRUG | Phase PHASE2 | Duchenne Muscular Dystrophy | ACTIVE_NOT_RECRUITING | NCT05540860 |
| Sevasemten Dose 4 | DRUG | Phase PHASE2 | Duchenne Muscular Dystrophy | ACTIVE_NOT_RECRUITING | NCT05540860 |
| Sevasemten Dose 3 | DRUG | Phase PHASE2 | Duchenne Muscular Dystrophy | ACTIVE_NOT_RECRUITING | NCT06100887 |
| Sevasemten Dose 2 | DRUG | Phase PHASE2 | Duchenne Muscular Dystrophy | ACTIVE_NOT_RECRUITING | NCT06100887 |
| Sevasemten Dose 1 | DRUG | Phase PHASE2 | Duchenne Muscular Dystrophy | ACTIVE_NOT_RECRUITING | NCT06100887 |
| Sevasemten 12.5 mg | DRUG | Phase PHASE2 | Becker Muscular Dystrophy | ACTIVE_NOT_RECRUITING | NCT05291091 |
| Sevasemten 5 mg | DRUG | Phase PHASE2 | Becker Muscular Dystrophy | ACTIVE_NOT_RECRUITING | NCT05291091 |
| Sevasemten 10 mg | DRUG | Phase PHASE2 | Becker Muscular Dystrophy | ACTIVE_NOT_RECRUITING | NCT05291091 |
| Sevasemten | DRUG | Phase PHASE2 | Becker Muscular Dystrophy | ENROLLING_BY_INVITATION | NCT06066580 |
| Placebo | DRUG | Phase PHASE1 | Healthy Adults | RECRUITING | NCT07177066 |
| EDG-5506 | DRUG | Phase PHASE1 | Muscular Dystrophies | COMPLETED | NCT05492734 |
Total products: 96